JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection
Fabien Zoulim(Hôpital de la Croix-Rousse), Jeysen Yogaratnam(Guilford College), Oliver Lenz(Janssen (Belgium)), Thomas Vanwolleghem(Erasmus MC), Adrian Streinu‐Cercel(Carol Davila University of Medicine and Pharmacy), Marı́a Buti(Vall d'Hebron Hospital Universitari), Joris Vandenbossche(Janssen (Belgium)), Christoph Sarrazin(St. Josefs Hospital), Willem Talloen(Janssen (Belgium)), John Fry(Janssen (United States)), Iurie Moscalu, J.M. Pascasio(Hospital Universitario Virgen del Rocío), Umesh Shukla(Janssen (United States)), Thierry Verbinnen(Janssen (Belgium)), Stefan Bourgeois(University of Antwerp), Javier Crespo(Universidad de Cantabria)
Cited by 116
Related Papers
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Hepatitis B Virus Resistance to Nucleos(t)ide Analogues
|Gastroenterology|2009|693
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346